Amgen's innovative first-line treatment for gastric cancer reduces the risk of death by 40%

Recently, Amgen announced at the ASCO annual meeting the latest results of its in-development anti-FGFR2b monoclonal antibody therapy bemarituzumab in a phase 2 clinical trial.
The test results showed that at a median follow-up time of 12.
5 months, the median overall survival (OS) of patients with FGFR2b positive and HER2-negative gastric cancer or gastroesophageal junction cancer (GEJ) who received bemarituzumab and chemotherapy as first-line treatment was 19.
2 Month, this value in the chemotherapy group was 13.
5 months (n=155, HR=0.
6, 95% CI: 0.
38, 0.
94).
Adding bemarituzumab extended the patient's median OS by 5.
7 months.

Gastric cancer is the fourth leading cause of cancer deaths in the world.

Bemarituzumab is a monoclonal antibody against FGFR2b.

In this phase 2 clinical trial, the bemarituzumab combination therapy was more effective in a subgroup of patients with >10% of tumor cells overexpressing FGFR2b.

In terms of safety, the number of adverse events in the bemarituzumab+ chemotherapy group (100%) and the chemotherapy group (98.
7%) was close.
The incidence of adverse corneal events in the Bemarituzumab+ chemotherapy group (67.
1%) was higher than that in the chemotherapy group (10.
4%).
Dry eye symptoms were the most common corneal adverse events, and most corneal adverse events were reversible.

Dr.
David M.
Reese, Executive Vice President of Research and Development of Amgen, said: "These latest results demonstrate the clinical benefits of the combination of bemarituzumab + chemotherapy for patients.
We look forward to advancing bemarituzumab to the phase 3 clinical development stage.
" (WuXi AppTec)